소아 성장 호르몬 결핍증(GHD) 시장 규모는 향후 몇 년 동안 높은 성장세를 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 의료 인프라 및 치료 접근성 확대, 성장 호르몬 치료의 발전, 인식 및 환자 옹호 증가, 정부 정책 및 의료 이니셔티브 지원, PGHD의 유병률 증가에 기인한 것으로 볼 수 있습니다. 예측 기간의 주요 트렌드에는 새로운 치료법 개발, 개인 맞춤형 치료 접근법, 제품 혁신, 원격 의료 및 원격 모니터링, 개인 맞춤형 의학 및 유전자 검사의 발전이 포함됩니다.
소아 질환의 유병률 증가는 소아 성장 호르몬 결핍증 시장의 성장을 견인할 것으로 예상됩니다. 소아 질환은 주로 유아기부터 청소년기까지 어린이에게 영향을 미치는 의학적 상태 또는 질병을 포함합니다. 이러한 질병의 발생 증가는 환경적 요인, 검출 방법의 발전, 생활 습관 변화, 유전적 소인, 어린이의 만성 질환 및 알레르기 발생률 증가에 기인할 수 있습니다. 이러한 질병은 성장 호르몬 생성을 담당하는 시상하부나 뇌하수체에 영향을 미쳐 소아 성장 호르몬 결핍증(GHD)을 유발할 수 있습니다. 예를 들어, 미국에 본부를 둔 정부 기관인 유엔아동기금(UNICEF)에 따르면 2022년에 5세 미만 어린이 약 490만 명이 하루 평균 1만 3,400명이 목숨을 잃을 것으로 예상됩니다. 5세 미만 사망의 주요 원인으로는 폐렴, 설사, 말라리아와 같은 전염병과 조산 및 분만 관련 합병증 등이 꼽혔습니다. 결과적으로 소아 질환의 유병률 증가는 소아 성장 호르몬 결핍증 시장의 확장을 촉진하고 있습니다.
이 시장에서 활동하는 기업들은 환자의 순응도와 편의성을 높이기 위해 주 1회 투여하는 지속형 인간 성장 호르몬 유사체를 비롯한 혁신적인 치료법 개발에 우선순위를 두고 있습니다. 주 1회 투여하는 지속형 인간 성장 호르몬(HGH) 유사체는 천연 인간 성장 호르몬의 변형 버전으로, 체내 작용 기간이 길어지도록 설계되었습니다. 예를 들어, 2023년 6월 미국 제약 회사인 화이자와 미국 의약품 회사인 옵코 헬스는 공동으로 미국 정부 기관인 식품의약국(FDA)으로부터 엔젠라(소마트로곤글라)의 승인을 받았다고 발표했습니다. 주 1회 투여하는 이 인간 성장 호르몬 유사체는 내인성 성장 호르몬의 분비 부족으로 성장 부전을 겪는 3세 이상의 소아 환자를 대상으로 합니다. 이 치료법은 일반적으로 매일 투여해야 하는 기존 치료법에 비해 주사 횟수를 줄여 환자의 순응도를 개선하는 것을 목표로 합니다. 임상 시험에 따르면 엔젠라는 매일 투여하는 성장 호르몬 치료와 유사한 효능을 보이며, 어린이와 그 가족에게 더 편리하고 관리하기 쉬운 솔루션을 제공하는 것으로 입증되었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 소아 성장 호르몬 결핍증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 소아 성장 호르몬 결핍증 시장 : 성장률 분석
- 세계의 소아 성장 호르몬 결핍증 시장 실적 : 규모와 성장(2019-2024년)
- 세계의 소아 성장 호르몬 결핍증 시장 예측 : 규모와 성장(2024-2029년, 2034년)
- 세계의 소아 성장 호르몬 결핍증 총 시장 규모(TAM)
제6장 시장 세분화
- 세계의 소아 성장 호르몬 결핍증 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 선천성 성장 호르몬 결핍증
- 후천성 성장 호르몬 결핍증
- 특발성 성장 호르몬 결핍증
- 세계의 소아 성장 호르몬 결핍증 시장 : 제품별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 재조합 인간 성장 호르몬(rhGH)
- 인간 성장 호르몬(HGH) 유사체
- 지속형 성장 호르몬
- 세계의 소아 성장 호르몬 결핍증 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 피하
- 근육 내
- 경구
- 세계의 소아 성장 호르몬 결핍증 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원 약국
- 소매 약국
- 온라인 약국
- 세계의 소아 성장 호르몬 결핍증 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 성장 호르몬 결핍증
- 특발성 저신장
- 터너 증후군
- 자궁 내 성장 지연(SGA)
- 프라다 윌리 증후군
- 기타 용도
- 세계의 소아 성장 호르몬 결핍증 시장 : 선천성 성장 호르몬 결핍증 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 단독 성장 호르몬 결핍증
- 뇌하수체 호르몬 복합 결핍증
- 세계의 소아 성장 호르몬 결핍증 시장 : 후천성 성장 호르몬 결핍증 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 뇌하수체 종양에 의한 성장 호르몬 결핍증
- 뇌 손상에 의한 성장 호르몬 결핍증
- 방사선 치료에 의한 성장 호르몬 결핍증
- 세계의 소아 성장 호르몬 결핍증 시장 : 특발성 성장 호르몬 결핍증 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 원발성 특발성 성장 호르몬 결핍증
- 이차성 특발성 성장 호르몬 결핍증
제7장 지역별 및 국가별 분석
- 세계의 소아 성장 호르몬 결핍증 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 소아 성장 호르몬 결핍증 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 소아 성장 호르몬 결핍증 시장 : 경쟁 구도
- 소아 성장 호르몬 결핍증 시장 : 기업 프로파일
- Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Eli Lilly and Company 개요, 제품 및 서비스, 전략 및 재무 분석
- Novo Nordisk A/S 개요, 제품 및 서비스, 전략 및 재무 분석
- Genentech Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck KGaA Darmstadt Germany 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Teva Pharmaceutical Industries Ltd.
- Mylan NV
- Sandoz International GmbH
- Sun Pharmaceutical Industries Ltd.
- I-Mab Biopharma Co. Ltd.
- Ipsen Pharma
- Gedeon Richter Plc
- Ferring Pharmaceuticals
- Celltrion Healthcare Co. Ltd.
- OPKO Health Inc.
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- 동-A ST Co. Ltd.
- Ascendis Pharma A/S
- AnkeBio
- Versartis Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 소아성장 호르몬 결핍증 시장(2029년) : 새로운 기회를 제공하는 국가
- 소아 성장 호르몬 결핍증 시장(2029년) : 새로운 기회를 제공하는 부문
- 소아성장 호르몬 결핍증 시장(2029년) : 성장 전략
제36장 부록
HBR
Pediatric growth hormone deficiency (PGHD) is a condition where the pituitary gland fails to produce adequate growth hormone, resulting in slow growth, short stature, and delayed puberty. This condition can be either congenital or acquired, with treatment usually involving recombinant human growth hormone (rhGH) therapy to help ensure normal growth and development.
The primary types of pediatric growth hormone deficiency are congenital GH deficiency, acquired GH deficiency, and idiopathic GH deficiency. Congenital growth hormone deficiency (GHD) is a rare condition present from birth, where the body cannot produce enough growth hormone. Various treatments are available, including recombinant human growth hormone (rhGH), human growth hormone (hGH) analogs, and long-acting growth hormones, which can be administered via subcutaneous, intramuscular, or oral routes. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used to address conditions such as growth hormone deficiency, idiopathic short stature, Turner syndrome, small for gestational age, Prader-Willi syndrome, and more.
The pediatric growth hormone deficiency market research report is one of a series of new reports from The Business Research Company that provides pediatric growth hormone deficiency market statistics, including pediatric growth hormone deficiency industry global market size, regional shares, competitors with a pediatric growth hormone deficiency market share, detailed pediatric growth hormone deficiency market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric growth hormone deficiency industry. This pediatric growth hormone deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pediatric growth hormone deficiency market size has grown strongly in recent years. It will grow from $3.80 billion in 2024 to $4.16 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth during the historic period can be credited to greater awareness of pediatric growth disorder treatments, enhanced diagnostic capabilities, increased investments in research and development of next-generation products, and the expansion of public insurance schemes.
The pediatric growth hormone deficiency market size is expected to see strong growth in the next few years. It will grow to $5.88 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth during the forecast period can be attributed to the expansion of healthcare infrastructure and access to care, advancements in growth hormone therapies, increased awareness and patient advocacy, supportive government policies and healthcare initiatives, and the rising prevalence of PGHD. Key trends in the forecast period include the development of novel therapies, personalized treatment approaches, product innovation, telemedicine and remote monitoring, as well as advancements in personalized medicine and genetic testing.
The rising prevalence of pediatric diseases is anticipated to drive the growth of the pediatric growth hormone deficiency market. Pediatric diseases encompass medical conditions or illnesses that primarily affect children from infancy to adolescence. The increasing occurrence of these diseases can be attributed to environmental factors, advancements in detection methods, lifestyle changes, genetic predispositions, and a growing incidence of chronic conditions and allergies among children. Such diseases can contribute to pediatric growth hormone deficiency (GHD) by impacting the hypothalamus or pituitary gland, which are responsible for growth hormone production. For example, according to the United Nations Children's Fund (UNICEF), a US-based government organization, approximately 4.9 million children under the age of five lost their lives in 2022, averaging 13,400 deaths per day. Leading global causes of under-five mortality included infectious diseases such as pneumonia, diarrhea, and malaria, along with complications from preterm birth and intrapartum-related issues. As a result, the increasing prevalence of pediatric diseases is fueling the expansion of the pediatric growth hormone deficiency market.
Companies operating in this market are prioritizing the development of innovative treatments, including long-acting, once-weekly human growth hormone analogs, to enhance patient compliance and convenience. A long-acting, once-weekly human growth hormone (HGH) analog is a modified version of natural human growth hormone, designed to have a prolonged duration of action in the body. For instance, in June 2023, Pfizer Inc., a US-based pharmaceutical company, and OPKO Health Inc., a US-based medication company, jointly announced the approval of NGENLA (somatrogon-ghla) by the Food and Drug Administration (FDA), a US-based government agency. This once-weekly human growth hormone analog is intended for pediatric patients aged three years and older who experience growth failure due to inadequate secretion of endogenous growth hormone. The treatment aims to improve patient adherence by reducing the frequency of injections, as traditional therapies typically require daily dosing. Clinical trials have demonstrated that NGENLA provides efficacy comparable to daily growth hormone treatments, offering a more convenient and manageable solution for children and their families.
In December 2024, Double Point Ventures, a US-based venture capital fund, acquired Lumos Pharma for $38 million. This acquisition is intended to accelerate the development of Lumos' lead therapeutic candidate, LUM-201, while expanding its portfolio of treatments for rare diseases. Lumos Pharma, a US-based biopharmaceutical company, specializes in developing therapies for rare diseases, particularly those associated with growth hormone deficiencies.
Major players in the pediatric growth hormone deficiency market are Pfizer Inc., Eli Lilly and Company, Novo Nordisk A/S, Genentech Inc., Merck KGaA Darmstadt Germany, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., I-Mab Biopharma Co. Ltd., Ipsen Pharma, Gedeon Richter Plc, Ferring Pharmaceuticals, Celltrion Healthcare Co. Ltd., OPKO Health Inc., Zhejiang Hisun Pharmaceutical Co., Ltd., Dong-A ST Co. Ltd., Ascendis Pharma A/S, AnkeBio, Versartis Inc., Changchun Changsheng Life Sciences Ltd.
North America was the largest region in the pediatric growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pediatric growth hormone deficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the pediatric growth hormone deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The pediatric growth hormone deficiency market consists of sales of synthetic growth hormone, growth hormone releasing hormone, and long-acting growth hormone therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pediatric Growth Hormone Deficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on pediatric growth hormone deficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for pediatric growth hormone deficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pediatric growth hormone deficiency market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Congenital GH Deficiency; Acquired GH Deficiency; Idiopathic GH deficiency
- 2) By Product: Recombinant Human Growth Hormone (rhGH); Human Growth Hormone (HGH) Analogs; Long-Acting Growth Hormones
- 3) By Route Of Administration: Subcutaneous; Intramuscular; Oral
- 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
- 5) By Application: Growth Hormone Deficiency; Idiopathic Short Stature; Turner Syndrome; Small For Gestational Age; Prader Willi Syndrome; Other Applications
- Subsegments:
- 1) By Congenital GH Deficiency: Isolated GH Deficiency; Combined Pituitary Hormone Deficiency
- 2) By Acquired GH Deficiency: GH Deficiency Due To Pituitary Tumors; GH Deficiency Due To Brain Injury; GH Deficiency Due To Radiation Therapy
- 3) By Idiopathic GH Deficiency: Primary Idiopathic GH Deficiency; Secondary Idiopathic GH Deficiency
- Companies Mentioned:Pfizer Inc.; Eli Lilly and Company; Novo Nordisk A/S; Genentech Inc.; Merck KGaA Darmstadt Germany
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Pediatric Growth Hormone Deficiency Market Characteristics
3. Pediatric Growth Hormone Deficiency Market Trends And Strategies
4. Pediatric Growth Hormone Deficiency Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Pediatric Growth Hormone Deficiency Growth Analysis And Strategic Analysis Framework
- 5.1. Global Pediatric Growth Hormone Deficiency PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Pediatric Growth Hormone Deficiency Market Growth Rate Analysis
- 5.4. Global Pediatric Growth Hormone Deficiency Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Pediatric Growth Hormone Deficiency Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Pediatric Growth Hormone Deficiency Total Addressable Market (TAM)
6. Pediatric Growth Hormone Deficiency Market Segmentation
- 6.1. Global Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Congenital GH Defficiency
- Acquired GH dificiency
- Idiopathic GH deficiency
- 6.2. Global Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Recombinant Human Growth Hormone (rhGH)
- Human Growth Hormone (HGH) Analogs
- Long-Acting Growth Hormones
- 6.3. Global Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Subcutaneous
- Intramuscular
- Oral
- 6.4. Global Pediatric Growth Hormone Deficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- 6.5. Global Pediatric Growth Hormone Deficiency Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Growth Hormone Deficiency
- Idiopathic Short Stature
- Turner Syndrome
- Small For Gestational Age
- Prader Willi Syndrome
- Other Applications
- 6.6. Global Pediatric Growth Hormone Deficiency Market, Sub-Segmentation Of Congenital GH Deficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Isolated GH Deficiency
- Combined Pituitary Hormone Deficiency
- 6.7. Global Pediatric Growth Hormone Deficiency Market, Sub-Segmentation Of Acquired GH Deficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- GH Deficiency Due To Pituitary Tumors
- GH Deficiency Due To Brain Injury
- GH Deficiency Due To Radiation Therapy
- 6.8. Global Pediatric Growth Hormone Deficiency Market, Sub-Segmentation Of Idiopathic GH Deficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Primary Idiopathic GH Deficiency
- Secondary Idiopathic GH Deficiency
7. Pediatric Growth Hormone Deficiency Market Regional And Country Analysis
- 7.1. Global Pediatric Growth Hormone Deficiency Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Pediatric Growth Hormone Deficiency Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Pediatric Growth Hormone Deficiency Market
- 8.1. Asia-Pacific Pediatric Growth Hormone Deficiency Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Pediatric Growth Hormone Deficiency Market
- 9.1. China Pediatric Growth Hormone Deficiency Market Overview
- 9.2. China Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Pediatric Growth Hormone Deficiency Market
- 10.1. India Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Pediatric Growth Hormone Deficiency Market
- 11.1. Japan Pediatric Growth Hormone Deficiency Market Overview
- 11.2. Japan Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Pediatric Growth Hormone Deficiency Market
- 12.1. Australia Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Pediatric Growth Hormone Deficiency Market
- 13.1. Indonesia Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Pediatric Growth Hormone Deficiency Market
- 14.1. South Korea Pediatric Growth Hormone Deficiency Market Overview
- 14.2. South Korea Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Pediatric Growth Hormone Deficiency Market
- 15.1. Western Europe Pediatric Growth Hormone Deficiency Market Overview
- 15.2. Western Europe Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Pediatric Growth Hormone Deficiency Market
- 16.1. UK Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Pediatric Growth Hormone Deficiency Market
- 17.1. Germany Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Pediatric Growth Hormone Deficiency Market
- 18.1. France Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Pediatric Growth Hormone Deficiency Market
- 19.1. Italy Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Pediatric Growth Hormone Deficiency Market
- 20.1. Spain Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Pediatric Growth Hormone Deficiency Market
- 21.1. Eastern Europe Pediatric Growth Hormone Deficiency Market Overview
- 21.2. Eastern Europe Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Pediatric Growth Hormone Deficiency Market
- 22.1. Russia Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Pediatric Growth Hormone Deficiency Market
- 23.1. North America Pediatric Growth Hormone Deficiency Market Overview
- 23.2. North America Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Pediatric Growth Hormone Deficiency Market
- 24.1. USA Pediatric Growth Hormone Deficiency Market Overview
- 24.2. USA Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Pediatric Growth Hormone Deficiency Market
- 25.1. Canada Pediatric Growth Hormone Deficiency Market Overview
- 25.2. Canada Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Pediatric Growth Hormone Deficiency Market
- 26.1. South America Pediatric Growth Hormone Deficiency Market Overview
- 26.2. South America Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Pediatric Growth Hormone Deficiency Market
- 27.1. Brazil Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Pediatric Growth Hormone Deficiency Market
- 28.1. Middle East Pediatric Growth Hormone Deficiency Market Overview
- 28.2. Middle East Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Pediatric Growth Hormone Deficiency Market
- 29.1. Africa Pediatric Growth Hormone Deficiency Market Overview
- 29.2. Africa Pediatric Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Pediatric Growth Hormone Deficiency Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Pediatric Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Pediatric Growth Hormone Deficiency Market Competitive Landscape And Company Profiles
- 30.1. Pediatric Growth Hormone Deficiency Market Competitive Landscape
- 30.2. Pediatric Growth Hormone Deficiency Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Genentech Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Merck KGaA Darmstadt Germany Overview, Products and Services, Strategy and Financial Analysis
31. Pediatric Growth Hormone Deficiency Market Other Major And Innovative Companies
- 31.1. Teva Pharmaceutical Industries Ltd.
- 31.2. Mylan N.V.
- 31.3. Sandoz International GmbH
- 31.4. Sun Pharmaceutical Industries Ltd.
- 31.5. I-Mab Biopharma Co. Ltd.
- 31.6. Ipsen Pharma
- 31.7. Gedeon Richter Plc
- 31.8. Ferring Pharmaceuticals
- 31.9. Celltrion Healthcare Co. Ltd.
- 31.10. OPKO Health Inc.
- 31.11. Zhejiang Hisun Pharmaceutical Co., Ltd.
- 31.12. Dong-A ST Co. Ltd.
- 31.13. Ascendis Pharma A/S
- 31.14. AnkeBio
- 31.15. Versartis Inc.
32. Global Pediatric Growth Hormone Deficiency Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Pediatric Growth Hormone Deficiency Market
34. Recent Developments In The Pediatric Growth Hormone Deficiency Market
35. Pediatric Growth Hormone Deficiency Market High Potential Countries, Segments and Strategies
- 35.1 Pediatric Growth Hormone Deficiency Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Pediatric Growth Hormone Deficiency Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Pediatric Growth Hormone Deficiency Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
